Cargando…
Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis
Up to date, survivin, a well-known inhibitor of apoptosis, has attracted considerable attention as a potential biomarker and therapeutic target in diffuse large B-cell lymphoma (DLBCL). Nevertheless, there still remains no consensus on heterogeneous results. Herein, a meta-analysis was performed to...
Autores principales: | Zhang, Ya, Wang, Jianhong, Sui, Xiaohui, Li, Ying, Lu, Kang, Fang, Xiaosheng, Jiang, Yujie, Wang, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616623/ https://www.ncbi.nlm.nih.gov/pubmed/26356696 http://dx.doi.org/10.1097/MD.0000000000001432 |
Ejemplares similares
-
Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP
por: Wang, Jing, et al.
Publicado: (2016) -
Coexistence of colon adenocarcinoma, diffuse large B-cell lymphoma, and myelodysplastic syndrome: A case report
por: Wang, Wei, et al.
Publicado: (2019) -
Effects of microRNA-21 on apoptosis by regulating the expression of PTEN in diffuse large B-cell lymphoma
por: Song, Jia, et al.
Publicado: (2017) -
Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era
por: Ho, Ching-Liang, et al.
Publicado: (2015) -
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)